Chiappini, S.; Vickers-Smith, R.; Harris, D.; Papanti Pelletier, G.D.; Corkery, J.M.; Guirguis, A.; Martinotti, G.; Sensi, S.L.; Schifano, F.
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals 2023, 16, 994.
https://doi.org/10.3390/ph16070994
AMA Style
Chiappini S, Vickers-Smith R, Harris D, Papanti Pelletier GD, Corkery JM, Guirguis A, Martinotti G, Sensi SL, Schifano F.
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals. 2023; 16(7):994.
https://doi.org/10.3390/ph16070994
Chicago/Turabian Style
Chiappini, Stefania, Rachel Vickers-Smith, Daniel Harris, G. Duccio Papanti Pelletier, John Martin Corkery, Amira Guirguis, Giovanni Martinotti, Stefano L. Sensi, and Fabrizio Schifano.
2023. "Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset" Pharmaceuticals 16, no. 7: 994.
https://doi.org/10.3390/ph16070994
APA Style
Chiappini, S., Vickers-Smith, R., Harris, D., Papanti Pelletier, G. D., Corkery, J. M., Guirguis, A., Martinotti, G., Sensi, S. L., & Schifano, F.
(2023). Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration’s FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset. Pharmaceuticals, 16(7), 994.
https://doi.org/10.3390/ph16070994
